[Top] [All Lists]

[e-drug] Independent Drug & Healthcare Newsletter March 2015

E-DRUG: Independent Drug & Healthcare Newsletter March 2015

N° 158 March 2015
View the table of contents for the current issue

"Biosimilars": towards fewer obstacles to their use
FEATURED REVIEW - The revised guideline on "biosimilars" proposed by the 
European Medicines Agency in 2013 dispenses with the excessive requirements of 
the prior version. These copies of biotechnology-derived drugs are a means of 
driving down the cost of treatment, which in turn helps ensure the 
sustainability of universal health care. Full review (4 pages) available for 
download by subscribers.
 Read more

In the March issue of Prescrire International:  Drugs to avoid in 2015
This is Prescrire's third consecutive annual review of "drugs to avoid". The 
listed drugs are clearly more dangerous than beneficial and should therefore 
not be used in any circumstance. The aim is to help healthcare professionals to 
choose safe, effective treatments and thereby avoid harming their patients.
Full text available for free download.
Read more

Multiple sclerosis: neither natalizumab nor alemtuzumab
With the benefit of hindsight, natalizumab (Tysabri°) has proved even more 
toxic than expected in multiple sclerosis patients. 
Evaluation of alemtuzumab (Lemtrada°) is too biased for its potential 
usefulness to be judged, however it exposes patients to severe adverse effects.
Read more

Teriflunomide (Aubagio°) is or will soon be on the market in several countries
Teriflunomide (Aubagio°) in the treatment of relapsing-remitting multiple 
sclerosis is reviewed in the March 2015 issue of Prescrire International 
The article includes a round-up of reviews from independent editorial teams in 
various countries.
 Read more

international <international@prescrire.org>

<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Independent Drug & Healthcare Newsletter March 2015, international <=